HENLEY-&-PARTNERS
21.4.2020 10:32:09 CEST | Business Wire | Press release
Unprecedented and highly volatile global conditions triggered by the COVID-19 pandemic are driving high-net-worth individuals to reassess the concept of secure investment value and how best to safeguard their families and their wealth against future shocks.
The virus is devastating countries in rapid succession - from struggling developing nations to global giants, no nation is being spared. Against a background of significant projected instability, investors with foresight are already engaging in their post-pandemic planning and re-assessing their wealth portfolios by opting to diversify via real estate–linked investment migration programs.
Leading international citizenship- and-residence-by-investment advisory firm Henley & Partners says before WHO announced the COVID-19 outbreak a pandemic, applications for Portugal’s popular Golden Residence Permit Program were on the rise. The first quarter of 2020 saw a 25% increase in interest in the program, with actual applications up by almost 50% compared to the same period in 2019. According to the latest Portuguese government data, 95% of Golden Residence Permit Program applicants have invested their funds in real estate, injecting approximately EUR 5 billion into the country’s economy over the past eight years.
Henley & Partners CEO Dr. Juerg Steffen says acquiring alternative residence or citizenship enables wealthy individuals to diversify their portfolios via a resilient investment solution, while at the same time contributing significantly to the economic wellbeing of the countries that offer programs. “Investment migration is a win-win solution for global investors and sovereign states alike. High-net-worth individuals favor European real estate-linked programs as they offer a unique hybrid investment opportunity that includes multiple yields from real estate, with all its traditional upside, as well as an alternative residence and/or citizenship with the option to relocate if they need too.”
In the recently published Henley Passport Index Q2 Update , FutureMap founder Dr. Parag Khanna predicts that the pandemic will prompt many to reconsider their global mobility options. “The combined effect of the COVID-19 pandemic on public health, the global economy, and social behavior may augur deeper shifts in our human geography — and our distribution around the world. As the curtain lifts, people will seek to move from poorly governed and ill-prepared places to more proactive countries with greater resilience and better medical care.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20200421005009/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 20266.5.2026 12:30:00 CEST | Press release
Compass management will host a conference call at 8:00 am ET (1:00 pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2026, and provide an update on recent developments, on May 13, 2026. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 13, 2026. A live webcast of the call will be available on the Compass Pathways website at: https://events.q4inc.com/attendee/144892287. The webcast will be archived for 30 days. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new p
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)6.5.2026 12:25:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to thirteen newly hired non-executive employees. The equity awards were granted on May 1, 2026 and consisted of options to purchase an aggregate of 125,335 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 59,625 shares. The options have an exercise price per share equal to $9.01, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Aircall Acquires Vogent to Advance Its AI Voice Agent Built Natively into Business Phones6.5.2026 12:03:00 CEST | Press release
Aircall, the AI-powered customer communications platform trusted by more than 22,000 businesses worldwide, today announced the acquisition of Vogent, an AI voice agent company. The acquisition adds a new layer of specialized voice AI technology to Aircall’s platform – strengthening the technology behind Aircall’s AI Voice Agent and moving it from already great to best-in-class. While AI agents' chat or email based communication channels have exploded in popularity, voice is its own discipline – with unique demands around timing, interruption handling, call flows, and production reliability. Voice channel also comes with the highest expectations from customers, further putting scrutiny around the readiness of the technology. For many businesses deploying AI voice agents, the experience has not lived up to the hype. With Vogent, Aircall enhances its AI Voice Agents with a deeper set of specialized AI technologies, including advanced speech models, more reliable turn-taking, and higher pr
AB InBev Wins Cannes Lions Creative Marketer of the Year for an Unprecedented Third Time6.5.2026 12:03:00 CEST | Press release
The world’s leading brewer’s approach to creativity as a competitive advantage results in strong performance and increased revenues The Cannes Lions International Festival of Creativity has announced AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD) as the 2026 Creative Marketer of the Year. The honorary accolade is presented to a marketer that has amassed a body of iconic, Lion-winning work over a sustained period of time. AB InBev’s continued commitment to using creativity as a growth lever across its portfolio resulted in it winning an impressive 37 Lions at last year’s Festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506536538/en/ AB InBev is the first company in Cannes Lions’ history to be honoured with the award for a third time. Since 2021 the global brewer has embarked on a journey of inorganic to organic growth, betting on creativity as a key competitive advantage that has contributed to strong perfor
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates6.5.2026 12:00:00 CEST | Press release
Total global revenues of $1.5 billion for the first quarter, an increase of 35% from the prior year Foundational BRUKINSA (zanubrutinib) global revenues of $1.1 billion for the first quarter, an increase of 38% from the prior year Diluted GAAP Earnings per American Depository Share (ADS) of $1.96 for the first quarter; non-GAAP diluted Earnings per ADS of $3.24 for the first quarter BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the first quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “These strong first-quarter results reinforce BeOne’s continued growth as a global oncology leader, driven by disciplined commercial execution, and underpinned by our established hematology leadership, and an impressive, rapidly emerging solid tumor pipeline. The sustained competitive advantages of our global superhighway for clinical development and manufacturing are now cle
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom